Biosimilars in India; current status and future perspectives
Many key biologics are scheduled to lose their patent by the year 2020, which will provide the opportunity to other biopharmaceutical companies to develop the similar biologics. Biosimilar or similar biologic used has increased in the recent year following the approval of the first biosimilar in ear...
Saved in:
Main Authors: | Bikash R Meher (Author), Sakthi Balan (Author), Rashmi R Mohanty (Author), Monalisa Jena (Author), Smita Das (Author) |
---|---|
Format: | Book |
Published: |
Wolters Kluwer Medknow Publications,
2019-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis
by: Biswa Mohan Padhy, et al.
Published: (2020) -
Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives
by: Rawla P, et al.
Published: (2018) -
Biosimilars: Current regulatory perspective and challenges
by: Diwakar Jha, et al.
Published: (2013) -
The biosimilars journey: current status and ongoing challenges
by: Igor Age Kos, et al.
Published: (2018) -
Biosimilars - drugs of the future
by: E. A. Eltcova, et al.
Published: (2014)